Skip to main content

Research Repository

Advanced Search

All Projects (77)

PIONEER5: Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment Nov 1, 2016 - Oct 31, 2019
Primary objective:
To compare the effect of once-daily dosing of 14 mg oral semaglutide versus placebo, both in combination with metformin and/or sulfonylurea, basal insulin alone or metformin in combination with basal insulin on glycaemic con... Read More about PIONEER5: Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment.

AX-8 Clinical Research Collaboration Jun 1, 2016 - May 31, 2018
Primary:
Study the efficacy of compound AX-8 in suppressing cough and upper airway symptoms in subjects with cough hypersensitivity syndrome.

Secondary:
Study the safety of compound AX-8.

TRANSFORM: Reducing Inequalities in Cancer Outcomes in Yorkshire: Realising our potential for innovation in Diagnosis, Patient Management, Survivorship and Palliative Care Research Sep 1, 2017 - Dec 31, 2026
The death rate is higher in Yorkshire than the rest of England resulting in about 200 extra deaths each year of which more than half are in Hull. There are other significant cancer outcome inequalities between different groups; for example poorer pe... Read More about TRANSFORM: Reducing Inequalities in Cancer Outcomes in Yorkshire: Realising our potential for innovation in Diagnosis, Patient Management, Survivorship and Palliative Care Research.

Does glycated hemoglobin variability in type 2 diabetes differ depending on the diabetes treatment used in the Qatari population: implication on diabetes complication risk Aug 1, 2016 - Jul 31, 2020
The purpose of this research is to better understand diabetes control and diabetes complications. It has been shown that fluctuation (changes) in long-term diabetes control may be related to the development of diabetes complications. In order to unde... Read More about Does glycated hemoglobin variability in type 2 diabetes differ depending on the diabetes treatment used in the Qatari population: implication on diabetes complication risk.

Can prevention of the activation of PAR2 prevent the release of procoagulant microvesicles from cancer cells, reduce the risk of VTE and contain the deterioration of the vasculature? Jul 1, 2015 - Jun 30, 2020
The study aims to demonstrate the indirect effect of Apixaban on suppressing the release of pro-inflammatory, pro-coagulant tissue factor-containing microvesicles, by inhibiting factor Xa and preventing the activation of PAR2. The study also demonstr... Read More about Can prevention of the activation of PAR2 prevent the release of procoagulant microvesicles from cancer cells, reduce the risk of VTE and contain the deterioration of the vasculature?.